Relationship between outcomes and relative dose intensity of lenvatinib treatment in patients with advanced hepatocellular carcinoma

Relationship between outcomes and relative dose intensity of lenvatinib treatment in patients with advanced hepatocellular carcinoma

Background and aims: Lenvatinib (LEN) is a newly developed tyrosine kinase inhibitor, and is approved as a first-line treatment for advanced hepatocellular carcinoma (HCC) in Japan. This retrospective multi-center study investigated the effect of the relative dose intensity (RDI) of LEN on response...

Full description

Bibliographic Details
Main Authors: Takamasa Ohki, Koki Sato, Mayuko Kondo, Eriko Goto, Takahisa Sato, Yuji Kondo, Masatoshi Akamatsu, Shinpei Sato, Hideo Yoshida, Yukihiro Koike, Shuntaro Obi
Format: Article
Language:English
Published: KeAi Communications Co., Ltd. 2020-12-01
Series:Liver Research
Subjects:
Advanced hepatocellular carcinoma
Lenvatinib (LEN)
Relative dose intensity (RDI)
Chemotherapy
Tyrosine kinase inhibitor
Online Access:http://www.sciencedirect.com/science/article/pii/S2542568420300519

Internet

http://www.sciencedirect.com/science/article/pii/S2542568420300519

Similar Items